We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The governments of the Democratic Republic of Congo (DRC) and Uganda have asked for a sleeping sickness drug to be made available before clinical trials -- which have shown positive preliminary results -- are completed next year, the Science and Development Network (SciDev.Net) reports.
Bristol-Myers Squibb (BMS) and AstraZeneca have announced a collaboration to develop and commercialize two investigational compounds being studied for the treatment of Type 2 diabetes.
The Italian Ministry of Health has asked Insmed to make its drug Iplex available to physicians in Italy to treat patients with amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder.
S*BIO, a biotech company based in Singapore, announced it has entered into a research collaboration with the Karolinska Institutet, a Swedish medical university.
Although more than 12 million people each year are bitten by dogs or snakes, or stung by scorpions, developing countries' capacity to treat these conditions is inadequate, according to the World Health Organization (WHO).
Healthcare spending in the U.S. totaled almost $2 trillion in 2005, or $6,697 per person, with total spending for prescription drugs in 2005 pegged at $200.7 billion, the Centers for Medicare & Medicaid Services (CMS) reported.
The Pharmaceutical Management Agency (PHARMAC) of New Zealand has announced it will expand access to two brands of the epilepsy drug lamotrigine, Mogine and Arrow-Lamotrigine, for the treatment of bipolar disorder.
The Kenyan government's decision last year to order a switch from sulfur-based drugs to artemisinin-based combination therapy (ACT) to treat malaria has caused a stir among the healthcare community, reports the Nairobi, Kenya-based East African Standard.
U.S. drugmakers Genentech and Seattle Genetics announced that they have entered into an exclusive worldwide license agreement for the development and commercialization of SGN-40, a humanized monoclonal antibody currently in Phase I and II trials in multiple cancer indications.